• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 7 Aug

    NextNRG Reports Preliminary July 2025 Revenue Growth of 236% Year-Over-Year

    Monthly Revenue Exceeds $8 Million for First Time in Company History Seventh Consecutive Record Month Drives NextNRG Closer to Profitability Timeline MIAMI, Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc. (Nasdaq: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered through its Next Utility… Read More..

    Share this:
  • 7 Aug

    Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

    -  Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study -  FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome -  Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study -  Orphan Drug Designation Granted by European Medicines Agency for QRX003 -  Rare Pediatric Disease… Read More..

    Share this:
  • 6 Aug

    MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

    Extension is Designed to Assess Early Efficacy and Patient Safety and Tolerability with Longer-Term Exposure to DA-1726 and Further Explore Non-Titrated Maximum Tolerated Dose Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming… Read More..

    Share this:
« Previous 1 2 3 4 5 6 … 252 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact